ClinicalTrials.gg
Not yet recruitingNCT07615894Updated May 29, 2026

WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)

A Phase 1 interventional study of WSK-IM02 in Advanced Solid Tumors, Malignant Pleural Effusions and Malignant Ascites, sponsored by WestVac Biopharma Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by WestVac Biopharma Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Pleural Effusion, Malignant with a site in China — 14 open to participants now, 15 under way, 1 of them phase 3. Pleural Effusion, Malignant · China.

Planned enrollment
28th of 28
9 · median 75
Started
2026
with 5 others
Phase 1
9 of 30
7 open now
Primary completion
2028-01
later than 10 of 14 live
Registered
27th of 30
by date

Among the 30 studies in Pleural Effusion, Malignant with a site in China, this one is the 28th largest by planned enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2026, is one of 9 in phase 1, reaches primary completion later than 10 of the 14 other live ones, and was the 27th registered.

Pleural Effusion, Malignant

169 studies on the registry are indexed under Pleural Effusion, Malignant; 39 are open to participants now.

Browse Pleural Effusion, Malignant studies →

Open to participants now

14 of the 30 studies in Pleural Effusion, Malignant with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Pleural Effusion, Malignant studies recruiting now, 15 (60%) set no upper age limit and 5 (20%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Pleural Effusion, Malignant with a site in China, or all of them as a file.
02

Study summary

This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural/intraperitoneal infusion of WSK-IM02 in patients with advanced solid tumors complicated by malignant pleural or peritoneal effusions who have failed standard of care.

03

Conditions studied

  • Advanced Solid Tumors
  • Malignant Pleural Effusions
  • Malignant Ascites
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤75 years.
  2. Voluntarily sign form.
  3. Patients with or cytologically confirmed advanced solid tumors.
  4. Histologically or cytologically confirmed malignant pleural/peritoneal effusion requiring drainage; or, in the absence of histologic/cytologic evidence, pleural effusion with clear imaging evidence of malignant pleural/peritoneal lesions on chest/abdominal CT and diagnosed as malignant pleural/peritoneal tumor in clinical practice.
  5. Have received standard systemic therapy and developed clinical symptoms of serous cavity .
  6. performance status: 0-2 points. Patients with ECOG 3 may be included if, in the investigator's judgment, removal of the effusion could improve the score to 2 or above.
  7. ≥3 months.
  8. Adequate major organ function.
  9. Able to tolerate thoracentesis/abdominocentesis and catheter placement, or already have a functional thoracic/abdominal drainage catheter in place, and agree to receive study drug treatment via this route.

Exclusion criteria

Exclusion Criteria:

  1. Participation in any other interventional clinical trial within 4 weeks prior to the first dose of study drug.
  2. Received local intracavitary therapy for pleural/peritoneal effusion (excluding diagnostic or symptom-relieving puncture/drainage) within 2 weeks prior to the first dose of study drug.
  3. Received extra-thoracic/extra-abdominal radiotherapy within 2 weeks prior to the first dose of study drug, or received radical radiotherapy to pleural/peritoneal or pulmonary/abdominal lesions within 8 weeks prior to enrollment (palliative radiotherapy to chest/abdomen is permitted).
  4. Underwent major thoracic or abdominal surgery within 4 weeks prior to the first dose of study drug and not fully recovered, or planned to undergo elective major surgery during the study period.
  5. Any toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1 at the start of study treatment.
  6. Symptomatic, uncontrolled central nervous system (CNS) or that, in the investigator's judgment, make the patient unsuitable for enrollment.
  7. Known (HIV) infection, active , active , or active syphilis infection.
  8. Active, uncontrolled infection requiring systemic antibiotics, antivirals, or antifungal therapy.
  9. Pregnant or breastfeeding women.
  10. Definite history of severe mental or cognitive disorders that, in the investigator's opinion, may affect study compliance or safety assessment.
  11. Presence of any active disease, or history of autoimmune disease requiring systemic therapy (topical or inhaled/intra-articular steroids are permitted).
  12. Require systemic corticosteroids or other immunosuppressants within 2 weeks prior to the first dose of study drug, and expected to require long-term use during the study.
  13. Have poorly controlled or severe cardiovascular disease.
  14. Have poorly controlled metabolic disease or complete/severe gastrointestinal obstruction requiring intervention.
  15. to the drug, any of its , liposomal formulations, or kanamycin.
  16. Have had a major thromboembolic event within 6 months prior to the first dose, or have a clear bleeding tendency.
  17. Active local infection at the administration site.
  18. Uncorrectable coagulation dysfunction that would pose a high risk for thoracentesis/abdominocentesis or catheter placement.
  19. Have any other concurrent, serious, and/or uncontrolled medical condition.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    intrapleural/intraperitoneal infusion of WSK-IM02

    Biological: WSK-IM02

Interventions

  • BiologicalWSK-IM02

    WSK-IM02 is an injectable pMVA-1 lipid complex

06

What researchers measure

Primary outcomes

  1. adverse events (AE)

    Adverse events defined as the number of participants with adverse events according to CTCAE v5.0.

    Time frame: up to 28 days

Secondary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the percentage of patients who achieve a response, which can either be complete response (complete disappearance of lesions) or partial response (reduction in the sum of maximal tumor diameters by at least 30% or more)

    Time frame: up to 12 months

  2. Progression-free survival (PFS)

    PFS is defined as the time from the administration of the first dose to first disease.

    Time frame: up to 12 months

  3. Overall survival (OS)

    OS is defined as the time from the administration of the first dose to death.

    Time frame: up to 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jan 2028, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jan 30, 2028
CompletionEst.
Jun 30, 2029
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07615894
Lead sponsor
WestVac Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jan 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
May 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion